Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lu-TLX250-TRAP
- Development stage
- Preclinical
- Lead developer
- Telix Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lu-TLX250-TRAP is a multi-functional radiopharmaceutical therapy (RPT) candidate developed by Telix Pharmaceuticals for the treatment of triple-negative breast cancer (TNBC). It is a fusion protein consisting of an anti-carbonic anhydrase IX (CAIX) antibody fused to the ectodomain of the TGFβ receptor II (TGFβRIIect), labeled with the beta-emitting radioisotope lutetium-177 (Lu-177). The agent is designed to localize to CAIX-expressing tumor cells, delivering cytotoxic radiation while simultaneously sequestering and neutralizing TGFβ in the tumor microenvironment. This dual mechanism aims to counteract TGFβ-mediated immunosuppression and radioresistance, thereby enhancing the recruitment and activity of CD4+ and CD8+ T cells and improving overall antitumor efficacy.
- Other names
- Lu-177-labeled TLX250-TRAPLu177-labeled TLX250-TRAPLu 177-labeled TLX250-TRAP177Lu-TLX250-TRAP
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on Lu-TLX250-TRAP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lu-TLX250-TRAP.